Growth in Hims & Hers Health is showing no signs of stopping, according to Morgan Stanley. Analyst Craig Hettenbach initiated the telehealth company with an overweight rating and $42 price target. That suggests 53.6% potential upside for the stock, which has already soared a whopping 251% this year on continued enthusiasm over its mental health, weight loss and dermatology treatments. Hettenbach's thesis also relies on advantages presented by the experienced board of Hims & Hers Health. Of the 14 who cover the company, seven rate it as a hold, while another six have a buy rating, LSEG data shows.

---

Persons: Morgan Stanley, Craig Hettenbach, Hettenbach, that's, Modest GLP Organizations: Netflix, Novo Nordisk, Pfizer